AcelRx Pharmaceuticals, Inc. (ACRX)
NASDAQ: ACRX · IEX Real-Time Price · USD
0.735
-0.084 (-10.26%)
At close: Dec 29, 2023, 4:00 PM
0.750
+0.015 (2.04%)
After-hours: Dec 29, 2023, 7:58 PM EST
AcelRx Pharmaceuticals Revenue
AcelRx Pharmaceuticals had revenue of $622.00K in the twelve months ending September 30, 2023, with 31,000.00% growth year-over-year. Revenue in the quarter ending September 30, 2023 was $117.00K. In the year 2022, AcelRx Pharmaceuticals had annual revenue of $1.77M, a decrease of -37.15%.
Revenue (ttm)
$622.00K
Revenue Growth
+31,000.00%
P/S Ratio
20.03
Revenue / Employee
$32,737
Employees
19
Market Cap
12.46M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 1.77M | -1.05M | -37.15% |
Dec 31, 2021 | 2.82M | -2.60M | -47.97% |
Dec 31, 2020 | 5.42M | 3.13M | 136.61% |
Dec 31, 2019 | 2.29M | 138.00K | 6.42% |
Dec 31, 2018 | 2.15M | -5.84M | -73.10% |
Dec 31, 2017 | 8.00M | -9.36M | -53.94% |
Dec 31, 2016 | 17.36M | -1.91M | -9.89% |
Dec 31, 2015 | 19.26M | 14.05M | 269.24% |
Dec 31, 2014 | 5.22M | -24.29M | -82.32% |
Dec 31, 2013 | 29.50M | 27.11M | 1,132.33% |
Dec 31, 2012 | 2.39M | 1.32M | 123.32% |
Dec 31, 2011 | 1.07M | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionACRX News
- 19 days ago - AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States - PRNewsWire
- 7 weeks ago - AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study - PRNewsWire
- 2 months ago - AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 - PRNewsWire
- 3 months ago - AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study - PRNewsWire
- 4 months ago - AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference - PRNewsWire
- 5 months ago - AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 5 months ago - AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 - PRNewsWire